SciClone Pharmaceuticals

SciClone reports synthetic dipeptide for boosting immune system shows oral bioavailability

Published in Medicine and Law Weekly, October 20th, 2006

SciClone Pharmaceuticals, Inc. (SCLN) reported phase 1 data indicating that SCV-07 taken orally was safe and led to circulating plasma concentrations similar to those obtained in previous phase 1 studies using a subcutaneous injection of SCV-07.

Importantly, SCV-07 taken orally resulted in only 10% plasma level variability between all volunteers in this study, demonstrating highly predictable plasma concentrations after oral dosing of this drug.

This phase 1 pilot study was designed to evaluate the oral availability of SCV-07 in healthy volunteers. A total of 24 volunteers were randomized into one of three groups receiving SCV-07 in an oral tablet,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-10-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry